Nippon Shinyaku (4516) · InitiativeFirst stated
In-licensing of exclusive U.S. commercialization rights for Tadekinig alfa and preparation for regulatory submission
First written in FY2027-H1. . Latest entry: FY2027-H1.
1entries
1years
0from disclosures
How it moved
Same theme, other companies
In-licensing of exclusive US commercialisation rights to Tadekinig alfa and preparations for a US marketing authorisation applicationA theme 1 companies write about · 0 as a headwind · 1 as a tailwind
No other company in this theme has enough history to compare yet.
Full recordFilings, disclosures and news, newest first